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Background: The aim of this study was investigate the relationship between ABCB1 and ABCC3 gene expressions
in peripheral blood cells (PBC) and the response to clopidogrel in patients with coronary arterial disease (CAD).
Methods: Twenty-six male CAD patients (50–70 years) under treatment with clopidogrel (75 mg/day) for at
least 5 days were selected. Blood samples were obtained to evaluate platelet reactivity and ABCB1 and ABCC3
mRNA expression. Platelet reactivity was measured in P2Y12 Reaction Units (PRU) using VerifyNow. RNA
was extracted from PBC and mRNA levels were measured by qPCR, using GAPD as a reference gene.
Results: Platelet response to clopidogrel was categorized in to PRU quartiles. Individuals with PRU values within
the ﬁrst quartile (Q1, b151 units) were considered good responders, while those who had PRU within the
fourth quartile (Q4, PRU>260) were considered non-responders. ABCC3 was 1.7 times more expressed in Q4
than in Q1 PRU group (p=0.048). Moreover, CAD patients with low ABCC3 expression (Qe1, b2.5×10−3)
had higher probability to have a good response to clopidogrel (OR: 18.00, 95%CI: 1.90–169.99, p=0.001). Uni-
variate linear regression analysis demonstrated that low ABCC3mRNA expression contributed with a reduction
of 73 PRU in relation to the patients with expression value higher than 2.5×10−3 (p=0.027). Neither ABCB1
mRNA levels nor clinical variables studied inﬂuenced PRU values.
Conclusions: Low ABCC3 mRNA expression in peripheral blood cells is associated with increased clopidogrel
response, but further studies are needed to describe the functional relationship of clopidogrel with the ABCC3.Crown Copyright © 2011 Published by Elsevier B.V. All rights reserved.1. Introduction
Clopidogrel is a prodrug that requires hepatic biotransformation
by cytochrome P450 to an active metabolite [1]. It is an antagonist
of the platelet adenosine diphosphate receptor that prevents platelet
agregation [2]. Other important antiagregation drug is a aspirin (acetyl-
salicylic acid), that action is reduces the activation of platelets by
irreversibly acetylating cyclooxygenase-1 (COX-1), and thereby reduces
thromboxane A2 by platelets [3].
Treatment with clopidogrel in combination with aspirin can pre-
vent recurrent ischaemic events after an acute coronary syndrome
or a percutaneous coronary intervention [4]. However, the responseo, Faculty of Pharmaceutical
alyses, Av Prof. Lineu Prestes.
11 3091 3660; fax: +55 11
11 Published by Elsevier B.V. All rigto clopidogrel has substantial interpatient variability that has been
associated with increased risk for recurrent cardiovascular events,
including stent thrombosis [5,6].
This variability has been related, at least in part, to polymorphisms
in genes involved in pharmacokinetic pathways that affects clopidogrel
bioavailability and eﬁcacy [7–9]. But other authors, suggest that varia-
tion in expression of ATP-binding cassette (ABC) membrane proteins,
are a family of efﬂux transporters, that can limit intestinal absorption
and intracellular concentrations of drugs [10,11]. Variants on genes
encoding ABC transporters have been implicated in low drug efﬁcacy
and safety [12,13].
The ABCB1 is the ﬁrst transporter membrane discovered in ABC
family and it is responsible for the efﬂux of a broad range of different
compounds including cytostatics, antiviral and lowering-cholesterol
drugs [14]. However, the role of ABCB1 in the pharmacokinetic of clo-
pidogrel is not well known. It has been shown that long exposure
(12–48 h) to high concentrations of clopidogrel (>10 μmol/l) down
regulates ABCB1 in Caco-2 cells, indicating a possible relationship of
this protein transport with clinical effectiveness of clopidogrel [7].hts reserved.
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important role in the efﬂux of endogenous glucuronides and conju-
gated drug metabolites across cell membranes [15]. A recent study
reported the detection of ABCC3 mRNA and protein expression in
human platelets [16]. The authors suggested that ABCC3 and other
ABC transporters may inﬂuence the transport of drugs on platelet
membrane interfering with the drug availability and efﬁcacy. The
−211T>C a variant located at the promoter region of the ABCC3
gene, that can inﬂuence their gene expression, was described to be
associated with the clinical outcome of chemotherapy in lung cancer
patients through alteration in the gene expression and consequently
in the pharmacological response [17].
This study investigated the relationship between ABCB1 and
ABCC3 mRNA expressions in peripheral blood cells (PBC) with clopi-
dogrel response of patients with coronary arterial disease (CAD).
2. Subjects and methods
2.1. Subjects and clinical protocol
Twenty six, male individuals with CAD, aged 50 to 70 years, who
underwent percutaneous coronary angioplasty (PCA) at the Hospital
do Meixoeiro (Vigo, Spain) were enrolled in this study from July to
December 2008. All individuals were under clopidogrel therapy
(75 mg/day)at least for5 daysprior toPCAandreceivedothermedication
such aspirin, betablockers, nitrates, statin and pumpprotons inhibitor.
Exclusion criteria: primary PCA; high bleeding risk; chronic renal
failure; under thienopyridine, glycoprotein IIb/IIIa inhibitor or warfarin
therapy; allergic reaction and also aspirin or clopidogrel contraindication.
Information on age, systolic and diastolic pressure, body mass
index (BMI), diabetes, Dyslipidemia, tobacco smoking, family history
of CAD, medications in use and time from last dose of clopidogrel
(TLDC) were recorded. This study was approved by the local Ethics
Committee and all subjects voluntarily provided written and
informed consent in agreement with Helsinki declaration.
2.2. Determination of platelet reactivity
Platelet reactivity was evaluated before PCA by turbidimetric opti-
cal detection of platelet aggregation using the VerifyNow P2RY12
assay (Accumetrics, San Diego, USA) according to manufacturer's
instructions. Brieﬂy, 2.0 ml of blood samples were drawn from an
antecubital vein with 3.2% citrate tubes. After 30 min at room temper-
ature, citrated-blood was transferred into standard cartridges con-
taining ﬁbrinogen-coated micro beads and 20 mmol/l of adenosine
diphosphate an agonist of purinergic receptor P2Y, G-protein
coupled, 12 (P2RY12). Platelet aggregation occurs and the system
converts luminosity transmittance of total blood in a result of platelet
response to clopidogrel inhibition, this result is denominated P2RY12
reaction units (PRU).
2.3. ABCB1 and ABCC3 mRNA expressions
Total RNA was isolated from whole blood samples with the PAX-
Gene Blood RNA system (PreAnalytiX, Hilden, Germany) by automated
Qiacube system (Qiagen, Valencia, USA) following the manufacturer's
protocols including a RNase-free DNase (Qiagen, Valencia, CA, USA)
step to remove genomic DNA. The quantity of RNA was measured
using a Nanodrop ND-1000 Spectrophotometer to give the yield and a
260/280 ratio. Agilent Bioanalyser Lab-on-a-chip RNA chips (Agilent
Technologies, Waldbronn, Germany) were also used for each sample
to check the quality by calculating RNA Integrity Number (RIN) scores,
samples with RINb5 were exclude. The RNA samples were stored at
−80 °C until later cDNA conversion. Isolated RNA samples were con-
verted to complementary DNA (cDNA) using High-Capacity cDNA Re-
verse Transcription Kits (Applied Biosystems, Foster City, USA) in aVeriti™ 96-Well Fast Thermal Cycler (Applied Biosystems, Foster City,
USA) under conditions described by the supplier. cDNA samples were
kept at −20 °C for further quantitative TaqMan® real-time PCR
(qPCR) analysis. ABCB1 and ABCC3 mRNA levels were measured by
qPCR using glyceraldehyde-3-phosphate dehydrogenase (GAPD) as a
reference gene. Primers and probes sequences used for ABCB1, ABCC3
and GAPDmRNA expressions were provided as “Assay on demand” for-
mat (Applied Biosystems, Foster City, USA). qPCR assayswas carried out
in 96-well plates of a 7500 Real-Time PCR System (Applied Biosystems,
Foster City, USA) using the following protocol: 40 cycles at 95 °C for 15 s
and at 60 °C for 1 min. The relative quantiﬁcation for each target gene
was measured using a comparative Ct method using the 2−deltaCt for-
mula, where deltaCt is the difference between the target gene Ct and
the GAPD Ct [18].
2.4. Statistical analysis
Statistical analyses were carried out using SPSS 15.0 for windows
(SPSS, Chicago, USA). Categorical variables were compared by Chi-
square test or Exact Fisher test and continuous variableswere compared
by Kruskal–Wallis test and t-test or Mann–Whitney test. Platelet aggre-
gation response to clopidogrel and ABCB1 and ABCC3mRNA expression
valueswere categorized in quartiles for statistic comparison (Q1, Q2, Q3
and Q4 for PRU; and Qe1, Qe2, Qe3 and Qe4 for mRNA expression).
Univariate logistic regression analysis was performed to evaluate
the variables associated with low mRNA expression levels of ABCC3
(model 1) and ABCB1 (model 2). Low mRNA expression was con-
sidered Qe1 group that was compared with the remaining groups
(Qe2+Qe3+Qe4). In both models, the highest response to clopido-
grel (Q1, PRUb151), age, BMI, hypertension, tobacco smoking, family
history of CAD, and TLDC were introduced as independent variables.
Diabetes and dyslipidemia had null value in one of the categorical
groups, therefore, they were not included as independent variables
in logistic regression analysis. Multivariate stepwise logistic regres-
sion was performed to evaluate the independent variables associated
with low ABCC3 mRNA expression, including age, BMI, TLDC and
good response clopidogrel (Q1, PRUb151), as covariates.
Univariate linear regressionwas performed the relationship between
PRU values and other variables, such as low ABCC3 (Qe1b2.50×10−3)
and ABCB1 (Qe1b5.08×10−3) expression values, age, BMI, hyperten-
sion, tobacco smoking, and family history of CADTLDC diabetes and
dyslipidemia. For all these analyses the signiﬁcance value was estab-
lished at the p-valueb0.050.
3. Results
3.1. Clinical data and response of clopidogrel
Clinical characteristics and response to clopidogrel data of the CAD
patients are presented in Table 1. Dyslipidemia (88%), hypertension
(62%) and patients with BMI>30 (23%) were the major risk factors
for CAD in this sample. Platelet response to clopidogrel was categorized
in to PRU quartiles. Individuals with PRU values within the ﬁrst quartile
(Q1, PRUb151)were considered good responders,while thosewhohad
PRU within the fourth quartile (Q4, PRU>260) were considered non-
responders. Age, BMI, clinical data and TLDC of the CAD patients did
not differ among clopidogrel response groups (p>0.05).
3.2. ABCB1 and ABCC3 mRNA expressions
ABCB1 and ABCC3 mRNA expresion levels in PBC were compared
among PRU quartile groups, as shown in Fig. 1. ABCC3 was 1.7 times
less expressed in the Q1 PRU group (2.7±1.2×10−3) than in the
Q4 PRU (4.5±1.7×10−3, p=0.048). On the other hand, no signiﬁ-
cant differences were observed in ABCB1 expression among PRU
quartile values (p=0.864).
Table 1
Clinical characteristics according to platelet clopidogrel response.
Variables Quartiles of clopidogrel response
Total Q1 Q2 Q3 Q4 p-value
Number of individuals 26 6 7 7 6
PRU, units 217±62 121±42 184±16 243±9 301±46 b0.001
Age, years 60±10 55±11 63±6 61±10 60±13 0.735
BMI, kg/m2 29±3 29±4 28±3 30±2 29±2 0.297
Hypertension, % 62 (16) 67 (4) 57 (4) 71 (5) 50 (3) 0.861
Diabetes, % 27 (7) 0 (0) 43 (3) 14 (1) 50 (3) 0.151
Dyslipidemia, % 88 (23) 100 (6) 71 (5) 86 (6) 100 (6) 0.307
Family history of CAD, % 12 (3) 17 (1) 0 (0) 29 (2) 0 (0) 0.279
Tobacco smoking, % 19 (5) 33 (2) 29 (2) 0 (0) 17 (1) 0.390
TLDC, h 11±9 8±10 15±8 5±7 16±8 0.153
Numbers of patients in parenthesis. Individuals were grouped in quartiles according to clopidogrel response using PRU values. Continuous variables are expressed as mean±SD.
Variables were compared by Chi-square or Kruskal–Wallis tests among ﬁrst (Q1), second (Q2), third (Q3) and fourth (Q4) quartiles of response to clopidogrel. PRU: P2RY12 reac-
tion units; BMI: Body Mass Index; CAD: coronary artery disease; TLDC: time from last dose of clopidogrel.
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mRNAb2.5×10−3) were compared with those having mRNA expres-
sion within the other quartiles (Qe2+Qe3+Qe4). Interestingly, low
ABCC3 expression (Qe1) was associated with low PRU mean values
(p=0.039) (Table 2). Other clinical variables did not inﬂuence ABCC3
mRNA levels in PBC.
Univariate logistic regression revealed that CAD patients with low
ABCC3mRNA expression (Qe1, b2.5×10−3) have 18 times more proba-
bility to be responsive to clopidogrel (OR: 18.000, 95%CI: 1.900–169.991,
p=0.011), as shown in Table 3. Others variables were not associated
with PBC ABCC3 mRNA levels in CAD patients. No relationship was
found between low ABCB1 mRNA expression (Qe1, b5.1×10−3) and
clinical variables and response to clopidogrel in CAD patients (Table 3).
Multivariate stepwise logistic regression conﬁrmed that patients
with low ABCC3mRNA expression had high probability to have a good
response to clopidogrel (OR: 30.755, 95%CI: 1.659–570.247,
p=0.021), whereas other variables included in this model (age, BMI
and TCLD) were not related with ABCC3mRNA levels in PBC (Table 4).
Univariate linear regression analysis demonstrated that low ABCC3
mRNA expression contributed with a reduction of 73 PRU in relation to
the patients with expression value higher than 2.5×10−3 (p=0.027)
(Table 5). In this model, the variables low ABCB1 mRNA expression,
age, BMI, hypertension, diabetes, dyslipidemia, tobacco smoking, and
family history of CAD and TLDC did not inﬂuence platelet response to
clopidogrel.
4. Discussion
Several risk factors for CAD such as hypertension, dyslipidemia, di-
abetes, tobacco smoking and family history of CAD have been foundFig. 1. ABCC3 and ABCB1 mRNA levels in peripheral blood cells according to clopidogrel re
expression was measured by qPCR using GAPD as reference gene (2−deltaCt method). First PRin this sample population, as it has been described previously [19].
However our results indicated that these risk factors did not inﬂuence
the platelet response to clopidogrel. The categorization in quartiles of
PRU values was a better approach to analyze the data of response to
clopidogrel. Good responders (PRUb151) were clearly differenciated
from non-responders (PRU>260), data that are in accordance with
those previously reported [20].
Cuisset et al. have evaluated three diferent methods for determina-
tion of clopidogrel response (ADP-induced platelet aggregation, Platelet
reactivity index Vasodilator-stimulated Phosphoprotein (VASP) and
Point of care Verify Now Assay) [21]. Even though, they have shown a
good correlation between the results from these methods, there was a
poor agreement to identify clopidogrel non-responders. It is likely that
the different cutoff values may had inﬂuenced these results.
In this study, diabetes was not associated with clopidogrel response
in CAD patients. However PRU Q1 group did not contain diabetic
patients suggesting association with low platelet response to clopido-
grel. It has been reported that the relationship between diabetes and
poor response to clopidogrel is problably due to an enhanced platelet
reactivity found in hyperglycemic status [22].
We also evaluated the ABCB1 and ABCC3mRNA expressions in PBC
and its possible association with platelet response to clopidogrel in
CAD patients. Low ABCC3 mRNA expresssors showed better response
to clopidogrel, independently of ABCB1mRNA expression and clinical
variables.
The mechanisms involved in modulation of ABCC3 mRNA expres-
sion in leukocytes are not clear. Bohan et al. have shown that induc-
tion of ABCC3 is hepatoprotective in cholestasis and suggested that
ABCC3may be transcriptionally regulated by liver receptor homolog 1
dependent on an intact TNFalpha signaling pathway [23]. Hepatocytesponse. Patients were grouped in quartiles of PRU values (Q1, Q2, Q3 and Q4). mRNA
U quartile (Q1) was compared with the others (Q2, Q3 and Q4) by Mann–Whitney test.
Table 2
Clinical characteristics according to ABCC3 mRNA expression.
Variables Quartiles of ABCC3 mRNA expression
Qe1 (6) Qe2+Qe3+Qe4 (20) p-value
ABCC3 mRNA levels 2.1±2.0×10−3 4.8±2.2×10−3 b0.001
Age, years 59±14 60±9 0.976
BMI, kg/m2 28±3 29±3 0.387
Hypertension, % 67 (4) 60 (12) 0.768
Diabetes, % 0 (0) 35 (7) ND
Dyslipidemia, % 100 (6) 85 (17) ND
Family history of CAD, % 17 (1) 10 (2) 0.654
Tobacco smoking, % 17 (1) 20 (4) 0.856
TLDC, hours 12±11 11±9 0.976
PRU, units 156±75 229±64 0.039
Numbers of patients in parenthesis. Individuals were grouped in quartiles according to
ABCC3 mRNA expression. Continuous variables are expressed as mean±SD. mRNA
expression was measured by qPCR using GAPD as reference gene (2−deltaCt method).
Variables were compared by Chi-square or Mann–Whitney tests between ﬁrst (Qe1)
and the others (Qe2+Qe3+Qe4) quartiles. PRU: P2RY12 reaction units; BMI: Body
Mass Index; CAD: coronary artery disease; TLDC: time from last dose of clopidogrel;
ND: not determined.
Table 4
Relationship between ABCC3 expression and clinical variables. Multivariate logistic re-
gression analysis.
Model Predictor OR 95% CI p-value
1 Low ABCC3 mRNA expression
PRU Q1 (b151 units) 30.755 1.659–570.247 0.021
Age 0.971 0.838–1.126 0.696
BMI, kg/m2 1.105 0.723–1.688 0.646
TLDC 0.999 0.997–1.002 0.603
ABCC3 expression was introduced as dependent variables considering as low mRNA
expression the ﬁrst quartile for ABCC3 (Qe1b2.5×10−3). mRNA expression was
measured by qPCR using GAPD as reference gene (2−deltaCt method). PRU Q1
(b151 units) represent good platelet response to clopidogrel. PRU: P2RY12 reaction
units; BMI: Body Mass Index; CAD: coronary artery disease; TLDC: time from last
dose of clopidogrel.
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liver tissues from HNF4a-HNull mice. Lu and co-workers have
reported that mice lacking HNF4a expression in liver have selective
loss of efﬂux transporters, including ABCC3 mRNA when compared
with wild-type mice [24].
Linear regression analysis demonstrated a positive correlation
between ABCC3 mRNA expression and response to clopidogrel
suggesting that ABCC3 may be involved in clopidogrel bioavailability
although we used whole blood cells as study model to analyze a the-
oretical relationship between clopidogrel and ABCC3 mRNA expres-
sion. Many studies uses this model of whole blood cells with act as
a marker of the pharmacologic response, since that the expression
of these cells may reﬂect the expression in other cells such as hepato-
cytes and enterocytes [14,25–27]. Study of Arazi et al., describe that
atorvastatin, a drug metabolized in hepatocytes cells, has differential
effects on SREBF1a and SCAP mRNA expressions in PBMC that areTable 3
Relationship between ABCB1 and ABCC3 expressions and clinical variables.
Model Predictor OR 95% CI p-value
1 Low ABCC3 mRNA expression
PRU Q1 (b151 units) 18.000 1.9–169.991 0.011
Age 0.994 0.905–1.092 0.905
BMI, kg/m2 0.846 0.577–1.240 0.390
Hypertension 0.750 0.110–5.109 0.769
Tobacco smoking 1.000 0.600–14.640 1.000
Family history of CAD 0.556 0.042–7.457 0.657
TLDC 1.000 0.998–1.002 0.852
2 Low ABCB1 mRNA expression
PRU Q1 (b151 units) 0.364 0.011–11.633 0.567
Age 0.91 0.759–10.925 0.314
BMI, kg/m2 1.756 0.845–3.649 0.130
Hypertension 0.38 0.014–10.171 0.564
Tobacco smoking 8.568 0.100–72.969 0.343
Family history of CAD 0.259 0.008–7.88 0.438
TLDC 1.002 0.998–1.005 0.246
Univariate logistic regression analysis.
ABCC3 and ABCC1 expressions were introduced as dependent variables considering as
low mRNA expression the ﬁrst quartile for ABCC3 (Qe1b2.5×10−3) and ABCB1
(Qe1b5.1×10−3). mRNA expression was measured by qPCR using GAPD as reference
gene (2−deltaCt method). PRU Q1 (b151 units) represent good platelet response to
clopidogrel. PRU: P2RY12 reaction units; BMI: Body Mass Index; CAD: coronary
artery disease; TLDC: time from last dose of clopidogrel.
PRU: P2RY12 reaction units; BMI: Body Mass Index; CAD: coronary artery disease;
TLDC: time from last dose of clopidogrel.associated with baseline transcription levels, triglycerides response
to atorvastatin. Therefore, mRNA expression of ABCC3 may play an
important role in determining clopidogrel intracellular concentration
and response.
The lack of relationship between ABCB1mRNA expressions in leu-
kocytes, response to clopidogrel and other clinical variables is sugges-
tive that this membrane transporter is not involved in clopidogrel
response. However more studies should be carried out to conﬁrm
this hypothesis. However, other author investigated the effect of
ABCB1 3435CbT polymorphism on ABCB1 expression in PBMCs of 69 in-
dividuals treatmentwith atorvastatin and not found signiﬁcant associa-
tion between this polymorphism and ABCB1mRNA expression [25].
One potential limitation of the present study is the small sample size
of clopidogrel responder group to analyze its associationwith the change
in mRNA expression. Therefore the effect of ABCC3 mRNA variants on
clopidogrel response should be tested in larger populations for better
evaluation of the pharmacogenomic role of these antiplatelet drug and
its relationship with membrane transporter.
In conclusion, low ABCC3 mRNA expression can be indicative of
better response to clopidogrel, independently of ABCB1 mRNA
expression and clinical variables. However, the molecular mechanisms
involved in regulation of ABCC3 expression and its effect on clopidogrel
response or if clopidogrel can be modify directly this gene expression
remain to be elucidated.Table 5
Relationship between response to clopidogrel and other variables. Univariate linear re-
gression analysis.
Dependent
variable
Independent
variable
B (SE) 95% CI R2 p-value
PRU (units)
Low ABCC3
expression
−73.9 (31.0) −136.0/−9.1 0.15 0.027
Low ABCB1
expression
−31.1 (33.8) −38.2/100.1 0.03 0.366
Age 0.4 (1.5) −2.7/3.4 0.01 0.812
BMI, kg/m2 4.1 (5.3) −6.7/15.0 0.02 0.439
Hypertension −6.8 (29.7) −68.2/64.5 0.01 0.820
Diabetes 35.4 (31.8) −30.2/101.1 0.05 0.277
Dyslipidemia 18.1 (45.2) −75.1/111.4 0.01 0.692
Tobacco smoking −12.2 (19.1) −51.7/27.3 0.02 0.529
Family history
of CAD
−0.4 (45.3) −93.9/99.1 0.01 0.992
TLDC 0.1 (0.1) −0.1/0.1 0.03 0.380
ABCC3 and ABCC1 expressions were introduced as independent variables considering
as low mRNA expression the ﬁrst quartile for ABCC3 (Qe1b2.5×10−3) and ABCB1
(Qe1b5.1×10−3). PRU: P2RY12 reaction units; BMI: Body Mass Index; CAD:
coronary artery disease; TLDC: time from last dose of clopidogrel; B (SE): regression
coefﬁcient (standard error); CI: conﬁdence interval; R2: coefﬁcient of determination.
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